NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017

• DOI: 10.6004/jnccn.2017.0166
• Publication Date: 2017-11-08T17:15:20Z
• Authors: Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A. Fenster...; Peter Forsyth; Jona Hattangadi-G...; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S. Loeffler; Paul L. Moots; Maciej M. Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K. Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C. Shrieve; Allen K. Sills; Lode J. Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh
• Keywords: Histology

For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations patients demonstrated prognostic value histologic phenotype, variability in outcomes within groups limited utility this system. Nonetheless, histology was only proven widely accessible tool available at time, thus it used for clinical trial entry criteria, therefore determined recommended treatment options. Research to identify molecular changes that underlie glioma progression has led discovery features greater diagnostic than Analyses these markers across from randomized trials shown some are also predictive response specific types treatment, which prompted significant options grade III (anaplastic) gliomas.